CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
CNS Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.99+0.14 (+2.87%)
Close on Oct 19, 2026
- Market cap
- $34.12M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -87.8% | -296.3% | |
| Return on assets | – | -79.6% | -183.0% | |
| Current ratio | – | 8.13 | 1.98 | |
| Interest coverage | – | -2896.6× | -1049.7× | |
| Diluted shares | – | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
CNS Pharmaceuticals generated $69.16M from operations and spent $36.43K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$69.16M
Used
$36.43K
Capital expenditure$36.43K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$15.85M
- Cash generatingOperating cash flow above zero-$13.81M
- Return on assets improvedROA up on the prior year-873.5% → -182.2%
- Earnings backed by cashOperating cash flow above net income-$13.81M vs -$15.85M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.43 → 1.98
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –